PMA P150013S024

Device
PD-L1 IHC 22C3 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150013
Supplement
S024
Product code
PLS
Decision date
2022-02-08
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Approval order statement
Approval for the removal of the gastric or gastroesophageal junction (GEJ) adenocarcinoma indication from the device labeling.

Current openFDA PMA Record#

Device
PD-L1 IHC 22C3 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150013
Supplement
S024
Product code
PLS
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Decision date
2022-02-08
Decision code
APPR
Date received
2022-01-31
Supplement type
Special (Immediate Track)
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
Approval for the removal of the gastric or gastroesophageal junction (GEJ) adenocarcinoma indication from the device labeling.